• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , May 24

RANBAXY Laboratories Ltd on Tuesday launched its approved generic formulation of Clarithromycin immediate release (IR) tablets in the US market.

The Office of Generic Drugs, US Food and Drug Administration, has determined that Ranbaxy's Clarithromycin tablets of 250 mg and 500 mg formulation can be expected to have the same therapeutic effect as an equivalent dose of Abbott's Biaxin Filmtab, the company said in a release.

"We are delighted to market this product as an addition to our ever growing generic product portfolio. Our plans are to bring this product to the market immediately," the Vice-President, Sales and Marketing, Ranbaxy Pharmaceuticals Inc, Mr Jim Meehan, said in the release.

The company's Clarithromycin tablets will be manufactured and marketed under the Ranbaxy label, it said.

Clarithromycin tablets are for the treatment of mild to moderate infections caused by susceptible strains of designated micro-organisms.

Ranbaxy Pharmaceuticals Inc, based in Jacksonville, Florida, US, is a wholly owned subsidiary of Ranbaxy Laboratories Ltd.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Xerox to hike stake in Indian arm to 100 pc 3 FIPB approval to be sought

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line